Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Aclaris Therapeutics

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), headquartered in Wayne, PA, is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

Aclaris Therapeutics
Finance

Aclaris Raises $50 Million to Fund Expanded Drug Trials

November 11, 2026November 9, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) raised $50 million in an October stock and warrant offering to finance an expanding pipeline of experimental treatments for inflammatory diseases, extending …

Aclaris Raises $50 Million to Fund Expanded Drug Trials Read More

Aclaris Therapeutics
Research

Aclaris Prioritizes Esophageal Drug Trial After Early Results

November 2, 2026November 1, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) plans to advance its experimental antibody ATI-052 into a Phase 2b trial for eosinophilic esophagitis in early 2027, concentrating development spending on …

Aclaris Prioritizes Esophageal Drug Trial After Early Results Read More
Aclaris Therapeutics
Public Companies

Aclaris CEO to Detail Drug Pipeline at Cantor Conference

September 7, 2026September 10, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) Chief Executive Officer Neal Walker will address investors Sept. 10 at the Cantor Global Healthcare Conference in New York as the clinical-stage …

Aclaris CEO to Detail Drug Pipeline at Cantor Conference Read More

Aclaris Therapeutics
Health / Medical

FDA Fast Track Status Advances Aclaris Lichen Planus Drug

August 13, 2026August 11, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) received Fast Track designation from the U.S. Food and Drug Administration for modzatinib as a potential treatment for moderate to severe lichen …

FDA Fast Track Status Advances Aclaris Lichen Planus Drug Read More
Aclaris Therapeutics
Finance

Aclaris Raises Capital as Drug Pipeline Spending Accelerates

August 11, 2026August 10, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics Inc. (NASDAQ: ACRS) raised $40.2 million through an at-the-market stock sale after the second quarter, extending its expected cash runway through the end of 2028 …

Aclaris Raises Capital as Drug Pipeline Spending Accelerates Read More

Aclaris Therapeutics
Business

Aclaris Expands Immunology Pipeline Ahead of Key Trial Data

May 16, 2026May 15, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) outlined plans for multiple mid- and late-stage clinical milestones this year as the biotechnology company advances experimental treatments for asthma, atopic dermatitis …

Aclaris Expands Immunology Pipeline Ahead of Key Trial Data Read More
Aclaris Therapeutics
Research

Aclaris Reports Phase 1a Results for ATI-052, Advances Pipeline

May 5, 2026May 3, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported full results from a Phase 1a clinical trial of its ATI-052 antibody and outlined plans to advance multiple programs, including selecting …

Aclaris Reports Phase 1a Results for ATI-052, Advances Pipeline Read More

Aclaris Therapeutics
Research

Aclaris to Present Phase 2a ATI-2138 Data at Dermatology Meeting

March 26, 2026March 25, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) will present new data from its Phase 2a trial of ATI-2138 in patients with moderate-to-severe atopic dermatitis at the 2026 American Academy …

Aclaris to Present Phase 2a ATI-2138 Data at Dermatology Meeting Read More
Aclaris Therapeutics
Research

Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis

March 25, 2026March 24, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) has completed patient enrollment in its Phase 2 trial of bosakitug in patients with moderate-to-severe atopic dermatitis, marking a development milestone for …

Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis Read More
Aclaris Therapeutics
Finance

Aclaris Reports 2025 Financial Results and Clinical Trial Updates

March 5, 2026March 4, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) reported its financial results for the fourth quarter and full year of 2025 and provided updates on several clinical-stage drug development programs, …

Aclaris Reports 2025 Financial Results and Clinical Trial Updates Read More

Posts pagination

1 2 … 4 Next

Trending News

  • Lancaster Man Convicted of Strangling Woman Three Times

  • Pottstown Foundation Offers $3,000 in Student Loan Relief

  • Police Seek Suspect in $200 PlayStation Controller Theft

  • Cecil College Earns Spot on TIME’s Top 250 Community Colleges

  • Lancaster Woman Accused of Trying to Set Home on Fire

Subscribe for Updates

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Court News

Lancaster Man Convicted of Strangling Woman Three Times

November 21, 2026November 20, 2026

suspect

Police Seek Suspect in $200 PlayStation Controller Theft

November 21, 2026November 20, 2026

Tiffany Michelle Seda

Lancaster Woman Accused of Trying to Set Home on Fire

November 21, 2026November 20, 2026

Copyright © 2026 MyChesCo.